Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 23, 2020

Merck reports positive Phase III data for pneumococcal vaccine

Merck (MSD) has reported positive results from two Phase III clinical trials of its investigational 15-valent pneumococcal conjugate vaccine, V114.

Merck (MSD) has reported positive results from two Phase III clinical trials of its investigational 15-valent pneumococcal conjugate vaccine, V114.

V114 is an investigational 15-valent pneumococcal conjugate vaccine being developed to prevent pneumococcal disease in adults and children. The vaccine comprises pneumococcal polysaccharides from 15 serotypes conjugated to a CRM197 carrier protein.

It includes 22F and 33F serotypes that are commonly related to invasive pneumococcal disease and not included in the pneumococcal conjugate vaccine currently licensed for adults.

The Phase III studies assess the safety, tolerability and immunogenicity of V114, and the vaccine candidate is said to have reached safety and immunogenicity objectives.

Data from the PNEU-WAY (V114-018) trial revealed that V114 induce an immune response to all 15 serotypes included in the vaccine, in adults aged 18 years or above with human immunodeficiency virus (HIV).

Meanwhile, the PNEU-FLU (V114-021) study results from healthy participants aged 50 years or older showed that V114 can be administered concomitantly with the quadrivalent influenza vaccine.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Merck Research Laboratories vaccine clinical research executive director in biologics Dr Luwy Musey said: “Results from these first two Phase III studies of V114 are encouraging and we look forward to sharing additional data in the future from our ongoing clinical development programme, including our pivotal studies assessing the immunogenicity of V114 and its potential to protect against the serotypes most likely to cause invasive disease.”

The Phase III clinical development programme for V114 involves 16 studies assessing its safety, tolerability and immunogenicity in populations at increased risk for pneumococcal disease.

Merck plans to work with the US Food and Drug Administration (FDA) and other regulators to potentially file for licensure of the vaccine.

In May last year, the company reported positive results from the Phase II trial of V114.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy